Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Breast Neoplasms 3 Pancreatic Adenocarcinoma 2 Stomatitis 1 Radiation Fibrosis Syndrome 1 Peripheral Nervous System Diseases 1 Neuroma, Acoustic 1 Neoplasms 1 Inflammation 1 Hypertension 1 Glioblastoma 1 Fibrosis 1 Fallopian Tube Neoplasms 1 Coronavirus Infections 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Camurati-Engelmann Syndrome 1 COVID-19 1 Brain Neoplasms 1

Interventions

Temozolomide 73 Bevacizumab 58 Radiotherapy 40 Radiosurgery 28 Carboplatin 23 Nivolumab 17 Etoposide 17 Cisplatin 17 pembrolizumab 16 Irinotecan 16 Ipilimumab 15 Magnetic Resonance Spectroscopy 14 Erlotinib Hydrochloride 14 Cyclophosphamide 14 Carmustine 14 Pemetrexed 13 Topotecan 10 Surgical Procedures, Operative 10 Capecitabine 10 Lapatinib 9 Filgrastim 9 Trastuzumab 8 Thalidomide 8 Sunitinib 8 Paclitaxel 8 Lomustine 8 Aminolevulinic Acid 8 encorafenib 7 binimetinib 7 Vincristine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Brain Neoplasms × Losartan × Clear all

NCT03951142 2023-11-01

ImPRESS

Oslo University Hospital

Phase 2 Unknown

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡